UNSPSC 51343006: Indinavir sulfate

This classification denotes a protease inhibitor and anti-hiv agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5W6YA9PKKH. European Medicines Agency schedules Indinavir sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02666MIG. Indinavir sulfate generally arises in the molecular formula C36H47N5O4.H2O4S. The term 'indinavir sulfate' is a European Medicines Agency European Public Assessment Report System designation.

UNSPSC 51343006 Indinavir sulfate is a Commodity code for a specific pharmaceutical active ingredient, but the recent state and local contract opportunities tagged under it do not reflect procurement of indinavir itself. Instead, the opportunities show state and local governments procuring finished pharmaceutical products and medical supplies through piggyback and competitive bidding processes — including antibiotic tablets, opioid-overdose reversal agents, and drug deactivation systems. The issuing bodies are state health departments and county governments executing strategic purchases for public health missions, often through established cooperative purchasing vehicles or agency-specific contracts. These procurements typically run for initial terms of one to three years with renewal options and involve standardized bidding processes with fixed pricing, delivery schedules, and compliance requirements such as E-Verify and drug-free workplace certifications.

Recent activity is sparse and geographically limited. The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026 for antibiotic tablets totaling $2,999,999.11 over three years; Seminole County, Florida posted an IFB on June 30, 2026 for naloxone and drug deactivation systems with a July 26, 2023 response deadline (a likely data error in the notice). The code shows little relevant recent activity for indinavir sulfate specifically, and the opportunities posted under it appear misaligned with the commodity's nominal scope.